{"disease":{"id":"chronic-inflammatory-demyelinating-polyneuropathy","name":"chronic inflammatory demyelinating polyneuropathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04292834","title":"A Registered Cohort Study of Immune-Mediated Neuropathies","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT06040567","title":"Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study","phase":"","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06858579","title":"A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Dianthus Therapeutics","has_results":false},{"nct_id":"NCT04281472","title":"A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":322,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT04280718","title":"A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":229,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT06858722","title":"Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":175,"lead_sponsor_name":"Zhongming Qiu","has_results":false},{"nct_id":"NCT05940922","title":"RWE-based Treatment Patterns and Outcomes in CIDP","phase":"","overall_status":"UNKNOWN","enrollment_count":170,"lead_sponsor_name":"RwHealth","has_results":false},{"nct_id":"NCT06290141","title":"A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT07091630","title":"A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT07154524","title":"Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","phase":"","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"University of Ulm","has_results":false},{"nct_id":"NCT06290128","title":"A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06605612","title":"Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":108,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT02027701","title":"Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT00278629","title":"Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT04589299","title":"Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT07027111","title":"Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Nuvig Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07478172","title":"Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Missouri-Columbia","has_results":false},{"nct_id":"NCT03397303","title":"Quantification of Nerve Stiffness in Neuropathies","phase":"NA","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT07337785","title":"CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Daishi Tian","has_results":false},{"nct_id":"NCT03166527","title":"Panzyga in CIDP Administered at Different Infusion Rates","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Vera Bril","has_results":false},{"nct_id":"NCT03684018","title":"Two Dose Levels of Privigen in Pediatric CIDP","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT07121985","title":"Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT07072676","title":"The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT06637072","title":"A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT05584631","title":"IVIG vs SCIG in CIDP","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT05492604","title":"Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP.","phase":"NA","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT02967679","title":"SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"MedDay Pharmaceuticals SA","has_results":true},{"nct_id":"NCT03779828","title":"Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP","phase":"","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT07343310","title":"A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Kine Sciences Co., Ltd.","has_results":false},{"nct_id":"NCT07526493","title":"Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03772717","title":"Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","phase":"NA","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT05014724","title":"CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT04777734","title":"Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT04825626","title":"An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Hope Biosciences Research Foundation","has_results":false}],"total":34},"guidelines":[],"source":"Drug Landscape verified database"}